Back to my company list

New

CellSight Diagnosis

The AI engine Fit Assessment

Beta

The company applies AI-focused technologies to healthcare by developing an AI-powered leukemia diagnosis platform, aligning with central AI focus and central Healthcare focus requirements.

Blurb

Operator of a healthtech platform intended to automate and enhance the process of diagnosing Leukemia. The company harnesses Artificial Intelligence and automated image analysis, pattern recognition and molecular profiling to efficiently detect leukemia which will be beneficial to both health authorities and patients and reduce the potential for human error in diagnosis, enabling healthcare professionals to intervene promptly, ultimately improving patient outcomes and decreasing the likelihood of disease advancement.

HQ Location

Canada

Founded

2024

Employees

1 - 10

Total funding raised

Not available

Funding Status

Not available

CellSight Diagnosis is a forward-thinking company founded by a dynamic team, including professionals from the fields

of dentistry and oncology. The goal is to revolutionize leukemia diagnosis through advanced technology and

comprehensive medical knowledge. They propose an innovative product that leverages artificial intelligence and image

processing to enable early, accurate, and rapid diagnosis of acute leukemia. This software platform utilizes deep neural custom models to distinguish immature leukemic blasts from normal cells, facilitating precise diagnosis

through microscopic image analysis. With a commitment to bridging the diagnostic gap and improving patient outcomes, CellSight Diagnosis is at the forefront of medical innovation, uniting expertise from diverse domains for a common purpose.